Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kamillex is a standardized topical and inhalational botanical drug product developed by Streuli Pharma. It is formulated as a liquid containing a standardized ethanolic extract of chamomile flowers (*Matricaria recutita*) enriched with added levomenol ((-)-alpha-bisabolol). Kamillex exerts anti-inflammatory, analgesic, antipruritic, and mild antiseptic properties. It is approved in Switzerland for a wide range of local inflammatory conditions, including oral and pharyngeal mucosal inflammation, skin irritations, superficial wounds, hemorrhoids, anal eczema, gynecological inflammations, and respiratory congestion (via inhalation).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kamillex.